SR One

Windward Bio is a clinical-stage biopharmaceutical company dedicated to enhancing outcomes for patients with advanced immunological diseases, focusing on severe respiratory conditions. The company is advancing a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 clinical trials. This antibody, administered subcutaneously, potently binds to the TSLP ligand, extending its half-life and silencing its effector functions. Windward Bio is also developing innovative bispecific programs for other immunological disorders, led by a team of experienced biopharmaceutical executives aiming to address significant unmet medical needs in this field.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists designed to manage these conditions by reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to address significant health challenges associated with metabolic disorders.

Avenzo Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for oncology, specifically targeting underserved and rare cancers. The company operates a specialized platform that focuses on creating novel treatments aimed at genomically defined cancer types. By prioritizing targeted therapies, Avenzo Therapeutics seeks to advance cancer treatment options for patients who may not have access to effective solutions, thus addressing significant gaps in the current therapeutic landscape.

Nomic is a bioengineering company focused on enhancing access to the human proteome, similar to the accessibility of the human genome. The company is developing the next-generation ELISA platform, known as nELISA, which is designed for high-throughput protein measurement. Nomic's solutions enable scientists to conduct protein profiling efficiently, allowing them to determine the scope and scale of their experiments. The platform features a cost-effective reagent system that integrates seamlessly with existing industry cytometers, facilitating high-throughput analysis and the creation of custom protein panels. By leveraging advanced technology, Nomic aims to empower researchers and nanotechnology developers to utilize DNA as a flexible and programmable linker, effectively addressing challenges such as cross-reactivity in protein measurements.

Elektrofi is a preclinical-stage company based in Boston, Massachusetts, focused on revolutionizing drug delivery to enhance patient experiences. Founded in 2016, Elektrofi specializes in a formulation system capable of processing a broad spectrum of therapeutic molecules, including large and complex proteins such as monoclonal antibodies, bispecifics, and fusion proteins. The company's technology aims to improve subcutaneous administration, enabling drug manufacturers to create innovative therapies that offer patients greater control over how they receive life-changing medicines.

Asceneuron SA, established in 2012 and headquartered in Lausanne, Switzerland, is a biotechnology subsidiary of Merck KGaA dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. The company focuses on progressive supranuclear palsy, orphan tauopathies, Alzheimer's disease, and Parkinson's disease, aiming to provide effective treatments where none currently exist or are limited in their benefits. Asceneuron operates by targeting the underlying causes of these debilitating conditions, such as abnormal tau protein deposits, with the goal of developing orally bioavailable therapeutics that can improve patients' lives and address the growing healthcare burden posed by neurodegenerative diseases.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Zenas BioPharma is a clinical-stage biopharmaceutical company headquartered in Florida, USA, that specializes in developing immune-based therapies for patients. The company’s lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to target both CD19 and FcγRIIb, which are found in B cell lineages. This innovative approach aims to inhibit the activity of cells involved in various autoimmune diseases while preserving their presence, thus avoiding depletion. Through its focus on these advanced therapies, Zenas BioPharma seeks to address unmet medical needs in the treatment of autoimmune conditions.

Nkarta Therapeutics is a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for treating various cancers and autoimmune diseases. Unlike T-cell therapies, NK cells have an inherent ability to recognize and destroy abnormal cells without genetic alteration, offering promise for diverse tumor types with potentially better tolerated side effects. Nkarta's approach involves leveraging its NK expansion platform technology alongside proprietary cell engineering techniques to generate a substantial supply of enhanced NK cells that can persistently target and eliminate cancer cells.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Alumis is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for autoimmune disorders. By leveraging a proprietary data analytics platform and biological insights, Alumis aims to transform the treatment landscape for patients suffering from these conditions. The company focuses on identifying and advancing therapeutics based on genetically validated targets, which enables the creation of targeted therapies that significantly improve patient outcomes. With a team of experts experienced in drug discovery and immunology, Alumis seeks to replace broad immunosuppression with more effective, targeted treatment options, ultimately enhancing the quality of life for individuals affected by autoimmune diseases.

CRISPR Therapeutics AG is a biotechnology company based in Zug, Switzerland, dedicated to developing transformative gene-based medicines for serious human diseases using CRISPR/Cas9 technology. This revolutionary gene-editing platform allows for precise changes to genomic DNA. The company's portfolio includes therapeutic programs targeting hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Their lead product candidate is CTX001, a gene-edited therapy for transfusion-dependent beta thalassemia or severe sickle cell disease, which has been approved as Casgevy in collaboration with Vertex Pharmaceuticals. Additionally, CRISPR Therapeutics is developing CTX110, an allogeneic CAR-T therapy targeting CD19-positive malignancies, and other programs like CTX120 for multiple myeloma and CTX130 for solid tumors and hematologic malignancies. The company also engages in regenerative medicine programs for diabetes and genetic disease treatments such as glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. CRISPR Therapeutics has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing innovative therapies for idiopathic pulmonary fibrosis (IPF) and other serious respiratory conditions. Headquartered in Seattle, Washington, with an additional office in San Diego, the company specializes in an inhaled formulation of pirfenidone, known as AP01. This formulation aims to enhance the amount of medication that reaches the lungs while minimizing side effects associated with oral treatments. Established in 2011, Avalyn Pharma is dedicated to improving care and outcomes for patients with severe respiratory diseases through its advanced therapeutic pipeline and novel inhaled therapeutics. Initially named Genoa Pharmaceuticals, the company rebranded to its current name in July 2017.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Established in 2019, the company specializes in genetic medicine by utilizing a proprietary platform that employs endogenous enzymes, specifically adenosine deaminase acting on RNA (ADAR), to precisely target and correct single point mutations in RNA transcripts. This innovative approach aims to restore the production of functional proteins, offering potential treatments for a variety of diseases, including those affecting genetic, cardiometabolic, complement-mediated, and central nervous system areas. ADARx Pharmaceuticals is dedicated to developing life-saving therapeutics that address genetic mutations and provide solutions for conditions that are currently considered incurable.

Avenzo Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for oncology, specifically targeting underserved and rare cancers. The company operates a specialized platform that focuses on creating novel treatments aimed at genomically defined cancer types. By prioritizing targeted therapies, Avenzo Therapeutics seeks to advance cancer treatment options for patients who may not have access to effective solutions, thus addressing significant gaps in the current therapeutic landscape.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Established in 2019, the company specializes in genetic medicine by utilizing a proprietary platform that employs endogenous enzymes, specifically adenosine deaminase acting on RNA (ADAR), to precisely target and correct single point mutations in RNA transcripts. This innovative approach aims to restore the production of functional proteins, offering potential treatments for a variety of diseases, including those affecting genetic, cardiometabolic, complement-mediated, and central nervous system areas. ADARx Pharmaceuticals is dedicated to developing life-saving therapeutics that address genetic mutations and provide solutions for conditions that are currently considered incurable.

Pulmocide Ltd is a biotechnology company based in London, United Kingdom, that specializes in the discovery and development of inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. Founded in 2007, Pulmocide focuses on creating a new generation of antifungal drugs specifically designed for inhaled administration. This method maximizes the delivery of medication directly to the lungs while reducing systemic exposure, thereby minimizing potential toxicities. The company's innovative treatments are intended to offer superior efficacy against respiratory aspergillosis and provide safer, more effective options for healthcare providers managing acute and chronic respiratory diseases.

Rezo Therapeutics is a biotechnology company that focuses on pioneering the integrated mapping of disease networks to develop precision therapeutics. Utilizing its proprietary Sequence to Systems to Drugs (SSD) platform, Rezo combines proteomics, genetics, structural biology, chemistry, and bioinformatics to create comprehensive maps of molecular disease networks. This innovative approach enables oncologists and researchers to identify novel targets and therapies with greater clarity and precision than traditional drug discovery methods. Initially concentrating on oncology, Rezo Therapeutics plans to expand its therapeutic focus through collaborations and partnerships, aiming to address a wide range of diseases.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

Ancora Biotech is a biotechnology company dedicated to the development of antibody biotherapeutics aimed at treating several life-threatening diseases. The company specializes in providing clinical development support for therapies targeting B cell cancers, as well as inflammatory and metabolic disorders, and chronic hepatitis B infections. By focusing on these critical areas, Ancora Biotech seeks to enable healthcare professionals to effectively treat patients suffering from serious health conditions.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Simcha Therapeutics is a biopharmaceutical company focused on developing engineered cytokine immunotherapy for cancer treatment. Founded in 2018 and headquartered in New Haven, Connecticut, the company utilizes directed evolution to create novel cytokines that enhance the immune system's ability to combat diseases. Its lead program, ST-067, is a designer IL-18 cytokine that has demonstrated significant antitumor effects in animal models, both as a standalone treatment and in combination with anti-PD-1 checkpoint inhibitors. This innovative approach aims to provide patients with more effective immunotherapies, thereby improving their ability to fight cancer.

Nomic is a bioengineering company focused on enhancing access to the human proteome, similar to the accessibility of the human genome. The company is developing the next-generation ELISA platform, known as nELISA, which is designed for high-throughput protein measurement. Nomic's solutions enable scientists to conduct protein profiling efficiently, allowing them to determine the scope and scale of their experiments. The platform features a cost-effective reagent system that integrates seamlessly with existing industry cytometers, facilitating high-throughput analysis and the creation of custom protein panels. By leveraging advanced technology, Nomic aims to empower researchers and nanotechnology developers to utilize DNA as a flexible and programmable linker, effectively addressing challenges such as cross-reactivity in protein measurements.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Established in 2019, the company specializes in genetic medicine by utilizing a proprietary platform that employs endogenous enzymes, specifically adenosine deaminase acting on RNA (ADAR), to precisely target and correct single point mutations in RNA transcripts. This innovative approach aims to restore the production of functional proteins, offering potential treatments for a variety of diseases, including those affecting genetic, cardiometabolic, complement-mediated, and central nervous system areas. ADARx Pharmaceuticals is dedicated to developing life-saving therapeutics that address genetic mutations and provide solutions for conditions that are currently considered incurable.

ARS Pharmaceuticals, Inc., established in 2015 and headquartered in San Diego, California, is a biopharmaceutical company focused on developing innovative treatments for severe allergic reactions. The company has created a novel intranasal epinephrine spray known as neffy, designed for the emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy utilizes a proprietary formulation that includes an absorption enhancer called Intravail, enabling it to deliver epinephrine effectively and rapidly through the nasal mucosa. This unique technology provides a convenient, reliable, and easy-to-use alternative for individuals at risk of life-threatening allergic reactions due to food, medications, or insect stings.

eFFECTOR Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, California, that specializes in the development of selective translation regulators for the treatment of cancer and other serious diseases. Founded in 2012, the company is pioneering a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). These drug candidates specifically target the eIF4F complex and its associated kinase, MNK 1/2, which play critical roles in protein synthesis and are linked to prominent cancer signaling pathways such as PI3K-AKT and RAS-MEK. eFFECTOR's products aim to inhibit pathways that drive tumor growth, survival, and immune evasion by regulating the expression of oncoproteins and immunosuppressive proteins. The lead candidate, tomivosertib, is currently being evaluated in a Phase 2b trial for non-small cell lung cancer in combination with pembrolizumab. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation in a Phase 1/2 trial, with further expansion cohorts anticipated. The company also collaborates with Pfizer to advance inhibitors targeting eIF4E.

Pulmocide Ltd is a biotechnology company based in London, United Kingdom, that specializes in the discovery and development of inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. Founded in 2007, Pulmocide focuses on creating a new generation of antifungal drugs specifically designed for inhaled administration. This method maximizes the delivery of medication directly to the lungs while reducing systemic exposure, thereby minimizing potential toxicities. The company's innovative treatments are intended to offer superior efficacy against respiratory aspergillosis and provide safer, more effective options for healthcare providers managing acute and chronic respiratory diseases.

BioTheryX, Inc. is a clinical-stage biopharmaceutical company based in Chappaqua, New York, that specializes in restoring protein homeostasis through innovative small molecule therapies. The company develops Protein Homeostatic Modulators, including a small molecular glue that targets cereblon for protein degradation, with applications in oncology, inflammation, and other diseases. BioTheryX employs its proprietary PRODEGY platform, which utilizes a library of cereblon binders to design targeted protein degraders (TPDs). Among its key products is BTX-A51, an oral multi-kinase inhibitor aimed at treating specific leukemic stem cell targets and preventing the transcription of oncogenic genes. Founded in 2007, BioTheryX aims to address unmet medical needs by leveraging its expertise in targeted protein degradation.

Arcellx is a clinical-stage biotechnology company focused on developing innovative immunotherapies, particularly in the realm of cell therapy, for patients with cancer and other serious diseases. The company aims to enhance the safety, effectiveness, and accessibility of these therapies. Arcellx's lead product candidate, CART-ddBCMA, is currently being investigated in a Phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. This therapy has received several designations from the U.S. Food and Drug Administration, including Fast Track and Orphan Drug status. Additionally, Arcellx is progressing its dosable and controllable CAR-T therapy, known as ARC-SparX, through two clinical programs targeting relapsed or refractory multiple myeloma and acute myeloid leukemia. Through these efforts, Arcellx seeks to contribute significantly to the advancement of cell therapy in modern medicine.

River 2 Renal is a developer of novel therapies intended to cure orphan diseases.

Design Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Solana Beach, California, focused on developing innovative therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company specializes in a novel class of small-molecule gene-targeted chimera therapeutics known as GeneTACTM molecules, which aim to modify disease progression by addressing the root causes of these conditions. Its lead program targets Friedreich’s ataxia, while additional efforts are directed toward conditions such as Fuchs endothelial corneal dystrophy and other degenerative diseases like Fragile X syndrome and myotonic dystrophy. Since its incorporation in 2017, Design Therapeutics has been dedicated to advancing its therapeutic candidates to potentially transform treatment options for patients suffering from these inherited disorders.

River 3 Renal is a developer of novel therapies designed to target orphan diseases in the renal space. The company's technology has the potential to address the unmet need in several kidney diseases, by further improving the standard of care, enabling medical practitioners to treat patients in a better way. River 3 Renal was established in 2020 in New York, USA.

F-Star Therapeutics is a biopharmaceutical company focused on developing novel bispecific antibody products aimed at improving upon current standards of care, particularly in cancer therapy. The company is uniquely positioned with a strong patent portfolio, enabling it to create and develop Fcab antibody fragments and bispecific antibodies by modifying the constant region of an antibody. F-Star's Modular Antibody Technology allows for rapid discovery and development of bispecific antibodies by adding binding sites to the constant region, facilitating easier production compared to other antibody formats. The company is leveraging this technology to build a pipeline of product candidates. Founded in 2006, F-Star has received significant funding from leading venture capital firms and strategic corporate investors. The company operates out of Cambridge, UK, with over 35 employees dedicated to research and development.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

Palleon Pharmaceuticals Inc. is a biotechnology company dedicated to developing innovative therapeutics that target glycan-mediated immune regulation for the treatment of cancer and inflammatory diseases. Founded in 2015 and based in Waltham, Massachusetts, the company specializes in glycoimmune checkpoint inhibitors, leveraging advanced insights from glycoscience and human immunology. Palleon's biotechnology platform aims to provide a novel approach to cancer treatment by targeting various immune cell types, thus offering physicians an expanded array of combination therapies to enhance treatment efficacy and address resistance to existing immuno-oncology agents. In addition to cancer, the company also focuses on therapeutics for inflammatory diseases, including autoimmunity and fibrosis.

Tranquis Therapeutics, Inc. is a biotechnology company based in San Mateo, California, focused on developing innovative immuno-therapeutics for neurodegenerative and aging-related diseases. Founded in 2016, the company emerged from pioneering neuro-immunology research and is dedicated to addressing the dysfunction of myeloid immune cells that plays a significant role in various nervous system disorders. Tranquis’ lead therapeutic candidate, TQS-168, is designed to treat conditions such as amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, and age-related cognitive impairment. The company's approach involves small molecules capable of crossing the blood-brain barrier, and it aims to initiate clinical development in orphan diseases like ALS and FTD before expanding to more common disorders, including Parkinson's and Alzheimer's disease. Tranquis Therapeutics strives to reduce the burden of these illnesses on patients, families, and society at large through its novel therapies.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Design Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Solana Beach, California, focused on developing innovative therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company specializes in a novel class of small-molecule gene-targeted chimera therapeutics known as GeneTACTM molecules, which aim to modify disease progression by addressing the root causes of these conditions. Its lead program targets Friedreich’s ataxia, while additional efforts are directed toward conditions such as Fuchs endothelial corneal dystrophy and other degenerative diseases like Fragile X syndrome and myotonic dystrophy. Since its incorporation in 2017, Design Therapeutics has been dedicated to advancing its therapeutic candidates to potentially transform treatment options for patients suffering from these inherited disorders.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

Arcellx is a clinical-stage biotechnology company focused on developing innovative immunotherapies, particularly in the realm of cell therapy, for patients with cancer and other serious diseases. The company aims to enhance the safety, effectiveness, and accessibility of these therapies. Arcellx's lead product candidate, CART-ddBCMA, is currently being investigated in a Phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. This therapy has received several designations from the U.S. Food and Drug Administration, including Fast Track and Orphan Drug status. Additionally, Arcellx is progressing its dosable and controllable CAR-T therapy, known as ARC-SparX, through two clinical programs targeting relapsed or refractory multiple myeloma and acute myeloid leukemia. Through these efforts, Arcellx seeks to contribute significantly to the advancement of cell therapy in modern medicine.

Nkarta Therapeutics is a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for treating various cancers and autoimmune diseases. Unlike T-cell therapies, NK cells have an inherent ability to recognize and destroy abnormal cells without genetic alteration, offering promise for diverse tumor types with potentially better tolerated side effects. Nkarta's approach involves leveraging its NK expansion platform technology alongside proprietary cell engineering techniques to generate a substantial supply of enhanced NK cells that can persistently target and eliminate cancer cells.

Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on designing and developing novel small molecule targeted therapies for oncology. The company specializes in creating next-generation tyrosine kinase inhibitors (TKIs) that address genetic drivers of cancer, catering to both TKI-naïve and TKI-pretreated patients. Its lead drug candidate, repotrectinib, is currently undergoing evaluation in the Phase I/II TRIDENT-1 trial for the treatment of patients with ROS1+ advanced non-small-cell lung cancer and those with ROS1+, NTRK+, or ALK+ advanced solid tumors. Additionally, Turning Point Therapeutics is advancing a pipeline that includes other multi-targeted drug candidates, such as TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. Founded in 2013, the company is dedicated to addressing the limitations of existing therapies through precision medicine in oncology.

Gotham Therapeutics Corp. is a biotechnology company based in New York, founded in 2017, that focuses on developing innovative treatments for patients with cancers, autoimmune disorders, and neurodegenerative diseases. The company specializes in a novel class of drugs that target the machinery of epitranscriptomics, which involves altering the activity of proteins that modify messenger ribonucleic acid (mRNA). By utilizing small molecules that inhibit the transcription of proteins through modifications to mRNA, Gotham Therapeutics aims to enhance treatment options and improve outcomes for individuals affected by serious health conditions.

Morphic Therapeutic is a biotechnology company focused on developing oral integrin therapies to address serious chronic diseases such as autoimmune disorders, cardiovascular issues, metabolic diseases, fibrosis, and cancer. The company leverages its expertise in integrins to create a pipeline of small-molecule inhibitors targeting various integrin pathways. This innovative approach aims to provide effective treatments for patients suffering from immunological, fibrotic, neoplastic, and vascular conditions, contributing to advancements in biopharmaceuticals.

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of a novel class of medicines known as Bicycles. These are synthetic short peptides designed to form two loops that stabilize their structure. The company's lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) currently undergoing Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also a BTC in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies targeting Nectin-4. Additionally, Bicycle is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to address therapeutic areas such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics was incorporated in 2009 and aims to address significant unmet medical needs in oncology and beyond.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Propeller Health is a digital health company focused on improving the management of chronic respiratory diseases such as asthma and COPD. The company offers a mobile platform that includes sensors, mobile apps, analytics, and services designed to support respiratory health management. The Propeller sensor attaches to users' inhalers and syncs wirelessly with their smartphones, tracking medication use, triggers, and symptoms. It provides personalized feedback and educational content based on the user's data. Users can set up medication reminders and alerts, and share their data with physicians and family members through the Propeller community. The platform is HIPAA compliant and stores users' data in a secure cloud infrastructure. Propeller Health collaborates with various healthcare organizations and has been recognized with several awards, including the TEDMED Innovation Showcase and White House Champion of Change. The company was founded by David Van Sickle, Greg Tracy, and Mark Gehring and is based in Wisconsin.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Zikani Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutics for patients with limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at treating a range of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Founded in 2014 and originally known as Macrolide Pharmaceuticals, Zikani is headquartered in Watertown, Massachusetts. The company's antibiotic compounds leverage advancements in synthetic chemistry and microbiology to address serious, multi-drug resistant gram-negative infections, which are a significant cause of severe health issues in the United States. Through its innovative approach, Zikani Therapeutics seeks to enhance patient outcomes and expand therapeutic options for challenging medical conditions.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Atox Bio Inc. is a biotechnology company based in Ness Ziona, Israel, with an additional office in North Carolina. Founded in 2003, the company specializes in developing immunomodulators aimed at treating critically ill patients facing severe acute inflammation due to infections. Atox Bio focuses on novel modulators of the immune response, targeting both adaptive and innate pathways that play crucial roles in managing infectious and inflammatory diseases, as well as ischemia/reperfusion injuries. The company's products are designed to improve outcomes for patients suffering from rare, life-threatening infections, demonstrating significant improvements in various clinical endpoints. By enhancing the host's ability to combat infections and minimizing tissue damage during acute inflammatory events, Atox Bio aims to address serious unmet medical needs in critical care settings.

Palleon Pharmaceuticals Inc. is a biotechnology company dedicated to developing innovative therapeutics that target glycan-mediated immune regulation for the treatment of cancer and inflammatory diseases. Founded in 2015 and based in Waltham, Massachusetts, the company specializes in glycoimmune checkpoint inhibitors, leveraging advanced insights from glycoscience and human immunology. Palleon's biotechnology platform aims to provide a novel approach to cancer treatment by targeting various immune cell types, thus offering physicians an expanded array of combination therapies to enhance treatment efficacy and address resistance to existing immuno-oncology agents. In addition to cancer, the company also focuses on therapeutics for inflammatory diseases, including autoimmunity and fibrosis.

eFFECTOR Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, California, that specializes in the development of selective translation regulators for the treatment of cancer and other serious diseases. Founded in 2012, the company is pioneering a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). These drug candidates specifically target the eIF4F complex and its associated kinase, MNK 1/2, which play critical roles in protein synthesis and are linked to prominent cancer signaling pathways such as PI3K-AKT and RAS-MEK. eFFECTOR's products aim to inhibit pathways that drive tumor growth, survival, and immune evasion by regulating the expression of oncoproteins and immunosuppressive proteins. The lead candidate, tomivosertib, is currently being evaluated in a Phase 2b trial for non-small cell lung cancer in combination with pembrolizumab. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation in a Phase 1/2 trial, with further expansion cohorts anticipated. The company also collaborates with Pfizer to advance inhibitors targeting eIF4E.

Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on designing and developing novel small molecule targeted therapies for oncology. The company specializes in creating next-generation tyrosine kinase inhibitors (TKIs) that address genetic drivers of cancer, catering to both TKI-naïve and TKI-pretreated patients. Its lead drug candidate, repotrectinib, is currently undergoing evaluation in the Phase I/II TRIDENT-1 trial for the treatment of patients with ROS1+ advanced non-small-cell lung cancer and those with ROS1+, NTRK+, or ALK+ advanced solid tumors. Additionally, Turning Point Therapeutics is advancing a pipeline that includes other multi-targeted drug candidates, such as TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. Founded in 2013, the company is dedicated to addressing the limitations of existing therapies through precision medicine in oncology.

Progyny, Inc. is a benefits management company focused on providing comprehensive fertility and family building benefits solutions for employers in the United States. Established in 2008 and headquartered in New York City, Progyny offers a range of services including a differentiated benefits plan design, personalized support through Patient Care Advocates, and access to a selective network of high-quality fertility specialists. The company's fertility benefits solution encompasses treatment services known as Smart Cycles, as well as an integrated pharmacy benefits solution called Progyny Rx, which facilitates access to necessary medications during treatment. Additionally, Progyny addresses the financial aspects of family building by covering surrogacy and adoption expenses for its clients and their employees. Formerly known as Auxogyn, Inc., the company rebranded to Progyny, Inc. in 2015.

ZappRx is a digital health company based in Boston, Massachusetts, founded in 2012. It specializes in providing a cloud-based platform that streamlines the process of ordering specialty medications for healthcare providers, specialty pharmacies, and biopharma companies. The platform facilitates secure digital interactions among providers, pharmacists, and payers, reducing reliance on traditional methods like faxes and phone calls. By automating prescription management and prior authorization processes, ZappRx enhances efficiency in collecting and maintaining necessary information for specialty prescribing. This includes details such as pharmacy information, payer requirements, and clinical history. The company's platform is utilized across various medical fields, including pulmonary, cardiology, and gastroenterology.

Pulmocide Ltd is a biotechnology company based in London, United Kingdom, that specializes in the discovery and development of inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. Founded in 2007, Pulmocide focuses on creating a new generation of antifungal drugs specifically designed for inhaled administration. This method maximizes the delivery of medication directly to the lungs while reducing systemic exposure, thereby minimizing potential toxicities. The company's innovative treatments are intended to offer superior efficacy against respiratory aspergillosis and provide safer, more effective options for healthcare providers managing acute and chronic respiratory diseases.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

Propeller Health is a digital health company focused on improving the management of chronic respiratory diseases such as asthma and COPD. The company offers a mobile platform that includes sensors, mobile apps, analytics, and services designed to support respiratory health management. The Propeller sensor attaches to users' inhalers and syncs wirelessly with their smartphones, tracking medication use, triggers, and symptoms. It provides personalized feedback and educational content based on the user's data. Users can set up medication reminders and alerts, and share their data with physicians and family members through the Propeller community. The platform is HIPAA compliant and stores users' data in a secure cloud infrastructure. Propeller Health collaborates with various healthcare organizations and has been recognized with several awards, including the TEDMED Innovation Showcase and White House Champion of Change. The company was founded by David Van Sickle, Greg Tracy, and Mark Gehring and is based in Wisconsin.

True North Therapeutics is a biotechnology company based in South San Francisco, California, founded in 2013 as a spin-out of iPierian. The company focuses on developing therapies that target the classical pathway of the immune system's complement system to address rare diseases with high unmet clinical needs. Its lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway, aiming to treat conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, antibody-mediated rejection, bullous pemphigoid, and other rare diseases in hematologic, kidney transplant, dermatology, and neurological spaces. True North Therapeutics was acquired by Bioverativ Inc.

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of a novel class of medicines known as Bicycles. These are synthetic short peptides designed to form two loops that stabilize their structure. The company's lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) currently undergoing Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also a BTC in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies targeting Nectin-4. Additionally, Bicycle is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to address therapeutic areas such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics was incorporated in 2009 and aims to address significant unmet medical needs in oncology and beyond.

Arch Oncology, Inc. is an immuno-oncology company focused on discovering and developing antibody therapeutics for the treatment of solid tumors and hematologic cancers. Founded in 2006 and headquartered in Brisbane, California, with a scientific research laboratory in St. Louis, Missouri, the company is known for its innovative approach to cancer treatment. Arch Oncology specializes in anti-CD47 antibodies, which represent a new class of checkpoint inhibitors that engage both the adaptive and innate immune responses. These functionally diverse antibodies not only inhibit immune checkpoints but also selectively target and kill tumor cells, providing patients with new therapeutic options in the fight against cancer.

Progyny, Inc. is a benefits management company focused on providing comprehensive fertility and family building benefits solutions for employers in the United States. Established in 2008 and headquartered in New York City, Progyny offers a range of services including a differentiated benefits plan design, personalized support through Patient Care Advocates, and access to a selective network of high-quality fertility specialists. The company's fertility benefits solution encompasses treatment services known as Smart Cycles, as well as an integrated pharmacy benefits solution called Progyny Rx, which facilitates access to necessary medications during treatment. Additionally, Progyny addresses the financial aspects of family building by covering surrogacy and adoption expenses for its clients and their employees. Formerly known as Auxogyn, Inc., the company rebranded to Progyny, Inc. in 2015.

Morphic Therapeutic is a biotechnology company focused on developing oral integrin therapies to address serious chronic diseases such as autoimmune disorders, cardiovascular issues, metabolic diseases, fibrosis, and cancer. The company leverages its expertise in integrins to create a pipeline of small-molecule inhibitors targeting various integrin pathways. This innovative approach aims to provide effective treatments for patients suffering from immunological, fibrotic, neoplastic, and vascular conditions, contributing to advancements in biopharmaceuticals.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

eFFECTOR Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, California, that specializes in the development of selective translation regulators for the treatment of cancer and other serious diseases. Founded in 2012, the company is pioneering a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). These drug candidates specifically target the eIF4F complex and its associated kinase, MNK 1/2, which play critical roles in protein synthesis and are linked to prominent cancer signaling pathways such as PI3K-AKT and RAS-MEK. eFFECTOR's products aim to inhibit pathways that drive tumor growth, survival, and immune evasion by regulating the expression of oncoproteins and immunosuppressive proteins. The lead candidate, tomivosertib, is currently being evaluated in a Phase 2b trial for non-small cell lung cancer in combination with pembrolizumab. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation in a Phase 1/2 trial, with further expansion cohorts anticipated. The company also collaborates with Pfizer to advance inhibitors targeting eIF4E.

Navitor Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing small molecule drugs that target specific nutrient-sensing proteins to modulate mTORC1 activity. This master regulator of cell growth and metabolism plays a crucial role in various age-related diseases. The company's proprietary platform allows for both selective inhibition and activation of mTORC1, offering potential treatments for conditions such as chronic kidney disease, depression, and other metabolic, neurodegenerative, autoimmune, and musculoskeletal diseases. Notable compounds include NV-5138, which activates mTORC1 and modulates sestrin, a natural activator of mTORC1, and the NValog program, which targets chronic kidney disease through selective mTORC1 inhibition. Founded in 2009, Navitor Pharmaceuticals aims to unlock the therapeutic potential of the mTOR pathway for a wide range of diseases.

True North Therapeutics is a biotechnology company based in South San Francisco, California, founded in 2013 as a spin-out of iPierian. The company focuses on developing therapies that target the classical pathway of the immune system's complement system to address rare diseases with high unmet clinical needs. Its lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway, aiming to treat conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, antibody-mediated rejection, bullous pemphigoid, and other rare diseases in hematologic, kidney transplant, dermatology, and neurological spaces. True North Therapeutics was acquired by Bioverativ Inc.

Puridify Limited is a bioprocessing company based in Stevenage, United Kingdom, founded in 2013 by Tom Haywood, Oliver Hardick, and Iwan Roberts. The company specializes in developing advanced purification technologies for the manufacturing of industrial biomolecules. Its flagship product, FibroSelect, utilizes a unique nanofiber-based platform that enhances purification efficiency while addressing the limitations found in traditional packed bed chromatography systems. This innovative technology is designed to provide consistent purification performance across various scales, making it suitable for the purification of complex biotherapeutics, including gene therapies, viral vectors, and fusion proteins. By improving the efficiency and cost-effectiveness of biopharmaceutical production, Puridify aims to advance the industry and support the growing demand for high-quality biomolecule products.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

Asceneuron SA, established in 2012 and headquartered in Lausanne, Switzerland, is a biotechnology subsidiary of Merck KGaA dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. The company focuses on progressive supranuclear palsy, orphan tauopathies, Alzheimer's disease, and Parkinson's disease, aiming to provide effective treatments where none currently exist or are limited in their benefits. Asceneuron operates by targeting the underlying causes of these debilitating conditions, such as abnormal tau protein deposits, with the goal of developing orally bioavailable therapeutics that can improve patients' lives and address the growing healthcare burden posed by neurodegenerative diseases.

Principia Biopharma Inc. is a late-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing innovative therapies for immune-mediated diseases. The company's lead product, rilzabrutinib, is an inhibitor undergoing Phase III clinical trials for pemphigus and pemphigus foliaceus, as well as Phase 1/2 trials for immune thrombocytopenia and Phase 2 trials for IgG4-related disease. Additionally, Principia is developing PRN2246/SAR442168, which is in Phase II for multiple sclerosis and other central nervous system conditions, alongside PRN473, a drug candidate in Phase I trials for immune-mediated diseases. Principia Biopharma maintains a collaboration agreement with Genzyme Corporation for the development of treatments for MS and other CNS diseases. Originally incorporated in 2008, the company is dedicated to addressing significant unmet medical needs in immunology and oncology through its innovative drug development platform.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

Gladius Pharmaceuticals Inc. is a biotechnology firm based in Montréal that focuses on developing innovative antibiotics to address life-threatening, multi-drug-resistant bacterial infections. The company is dedicated to creating novel drug candidates that demonstrate broad-spectrum efficacy against gram-negative pathogens. Gladius's antibiotics aim to assist in the empiric treatment of these infections and have the potential to replace older generation cephalosporins, thereby providing physicians with effective treatment options for challenging bacterial infections.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

Akamis Bio is a clinical-stage oncology company dedicated to advancing cancer treatment through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops a portfolio of therapeutics specifically targeting solid tumors, aiming to enhance patients' immune responses to recognize and eradicate cancer cells. By harnessing a proprietary intravenously administered viral platform, Akamis Bio focuses on delivering effective gene therapies that address the needs of cancer patients, striving to improve their quality of life and treatment outcomes.

CRISPR Therapeutics AG is a biotechnology company based in Zug, Switzerland, dedicated to developing transformative gene-based medicines for serious human diseases using CRISPR/Cas9 technology. This revolutionary gene-editing platform allows for precise changes to genomic DNA. The company's portfolio includes therapeutic programs targeting hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Their lead product candidate is CTX001, a gene-edited therapy for transfusion-dependent beta thalassemia or severe sickle cell disease, which has been approved as Casgevy in collaboration with Vertex Pharmaceuticals. Additionally, CRISPR Therapeutics is developing CTX110, an allogeneic CAR-T therapy targeting CD19-positive malignancies, and other programs like CTX120 for multiple myeloma and CTX130 for solid tumors and hematologic malignancies. The company also engages in regenerative medicine programs for diabetes and genetic disease treatments such as glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. CRISPR Therapeutics has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc.

CRISPR Therapeutics AG is a biotechnology company based in Zug, Switzerland, dedicated to developing transformative gene-based medicines for serious human diseases using CRISPR/Cas9 technology. This revolutionary gene-editing platform allows for precise changes to genomic DNA. The company's portfolio includes therapeutic programs targeting hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Their lead product candidate is CTX001, a gene-edited therapy for transfusion-dependent beta thalassemia or severe sickle cell disease, which has been approved as Casgevy in collaboration with Vertex Pharmaceuticals. Additionally, CRISPR Therapeutics is developing CTX110, an allogeneic CAR-T therapy targeting CD19-positive malignancies, and other programs like CTX120 for multiple myeloma and CTX130 for solid tumors and hematologic malignancies. The company also engages in regenerative medicine programs for diabetes and genetic disease treatments such as glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. CRISPR Therapeutics has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc.

True North Therapeutics is a biotechnology company based in South San Francisco, California, founded in 2013 as a spin-out of iPierian. The company focuses on developing therapies that target the classical pathway of the immune system's complement system to address rare diseases with high unmet clinical needs. Its lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway, aiming to treat conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, antibody-mediated rejection, bullous pemphigoid, and other rare diseases in hematologic, kidney transplant, dermatology, and neurological spaces. True North Therapeutics was acquired by Bioverativ Inc.

ZappRx is a digital health company based in Boston, Massachusetts, founded in 2012. It specializes in providing a cloud-based platform that streamlines the process of ordering specialty medications for healthcare providers, specialty pharmacies, and biopharma companies. The platform facilitates secure digital interactions among providers, pharmacists, and payers, reducing reliance on traditional methods like faxes and phone calls. By automating prescription management and prior authorization processes, ZappRx enhances efficiency in collecting and maintaining necessary information for specialty prescribing. This includes details such as pharmacy information, payer requirements, and clinical history. The company's platform is utilized across various medical fields, including pulmonary, cardiology, and gastroenterology.

Thrasos is a bio-therapeutics company dedicated to discovering and developing targeted therapies for severe organ failure, with a primary emphasis on kidney diseases. The company's lead program, THR-184, aims to prevent and treat acute kidney injury (AKI). Additionally, Thrasos is advancing a preclinical development program that addresses chronic kidney disease (CKD). The company also focuses on developing innovative treatments for rare kidney-related conditions, such as myeloma cast nephropathy, which occurs when protein aggregates obstruct renal tubules, leading to the risk of permanent kidney damage. Through its efforts, Thrasos seeks to provide timely and effective treatment options for patients suffering from these serious kidney issues.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Zikani Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutics for patients with limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at treating a range of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Founded in 2014 and originally known as Macrolide Pharmaceuticals, Zikani is headquartered in Watertown, Massachusetts. The company's antibiotic compounds leverage advancements in synthetic chemistry and microbiology to address serious, multi-drug resistant gram-negative infections, which are a significant cause of severe health issues in the United States. Through its innovative approach, Zikani Therapeutics seeks to enhance patient outcomes and expand therapeutic options for challenging medical conditions.